Artificial intelligence is beginning to outperform humans in narrow but economically consequential tasks, raising anxieties about job security and even agency. We are seriously discussing the possibility of losing control over AI. And one of the proposed ways of dealing with it is integration: linking the nervous system to digital tools through the brain-computer interfaces (BCIs).
In recent years, GLP-1–based weight-loss drugs have decisively moved beyond a narrow medical topic and become a mainstream subject of discussion in the US, Europe, and Canada. Explosive demand growth, intensifying competition, and expectations of change driven by patent timelines have turned the search for Ozempic alternatives into a practical question: what should you choose if Ozempic is hard to obtain, too expensive, or poorly tolerated?
The word “rejuvenation” covers everything from cosmetics and supplements to lab work that tries to change how cells age — and, in turn, how age-related disease risk builds up. This article is a short guide to the science-backed version of that conversation: what geroscience is, what the Hallmarks of Aging are, and why investors are pouring billions into the space.
European Association of Preventive Cardiology gathering on preventive cardiology; expert-led sessions on prevention-first approaches, risk reduction, lifestyle medicine; 500+ international attendees.
Professionals from pharma, biotech, and device industries focus on manufacturing, bioprocessing, development technologies; exhibition, technical sessions, networking on efficiency, quality, compliance across product lifecycle.
Canadian biotech company Providence Therapeutics has announced its support for the PaedNEO-VAX clinical study — a program testing personalized mRNA vaccines for children and teens with the most severe, treatment-resistant brain tumors. The project is set to launch in Australia in March 2026, and organizers say patient enrollment will run through a network of 7–8 pediatric hospitals and clinics across several states.
Language models are widely capable of answering health-related questions — a topic that the media have covered extensively. These are truly remarkable advancements. However, the process of implementing them into real life rarely draws the same attention; it is accompanied by tedious paperwork and annoying safety issues.
Pfizer has released mid-stage (Phase 2b) VESPER-3 results: its experimental drug PF’3944 (previously known as MET-097i and brought into Pfizer via the Metsera deal) helped people with obesity or overweight lose up to 12.3% of body weight (placebo-adjusted) by week 28. The headline feature is the dosing schedule: patients started with weekly injections during dose escalation, then switched to a once-monthly maintenance shot. Pfizer says there was no clear weight-loss “plateau” by week 28, and the trial continues through week 64.
Modern medical practice is virtually unthinkable without numerous wearable electronic devices. Miniature flexible devices that continuously monitor blood glucose levels, blood pressure, pulse, or other vital parameters have become an integral part of daily life and an indispensable element of diagnostics and treatment.
Medtronic announced on February 3, 2026, its intent to exercise its option to acquire CathWorks, an Israeli medical device company specializing in AI-driven coronary artery disease diagnostics, in a deal valued at up to $585 million plus potential undisclosed earn-out payments. The acquisition, pending U.S. Federal Trade Commission clearance, is expected to close by the end of Medtronic’s fiscal year 2026.